A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.

Trial Profile

A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms PHILEMON
  • Most Recent Events

    • 27 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
    • 27 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
    • 06 Dec 2016 According to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology, accrual of 50 patients was completed in 12 months, June 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top